VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
LEGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
LEGNLegend Biotech Corporation
$18.57$3.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLEGNRevenue History

LEGN logoLegend Biotech Corporation (LEGN) Revenue History

Annual and quarterly revenue from 2017 to present

TTM Revenue$1.27B▲ +$242.4M vs FY2025
YoY Growth+51.9%Excellent
Q2 2026$387.5M+51.9% YoY · +27.0% QoQ
Revenue CAGR
3Y+106.4%
→
5Y+68.8%
→
10Y—
Growth accelerating ↑
Best Fiscal Year$1.03B (2025)
Best Quarter$387.5M (Q2 2026)
Revenue per Share$6.87
Revenue per Employee$397K

LEGN Revenue Over Time (2017–2025)

LEGN Revenue Growth History

7 of 8 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2017—
2018+108.2%
2019+25.8%
2020+21.4%
2021-8.2%
2022+70.0%
2023+143.7%
2024+120.0%
2025+64.0%
FY2017 revenue growth
N/A
FY2018 revenue growth
+108.2%
FY2019 revenue growth
+25.8%
FY2020 revenue growth
+21.4%
FY2021 revenue growth
-8.2%
FY2022 revenue growth
+70.0%
FY2023 revenue growth
+143.7%
FY2024 revenue growth
+120.0%
FY2025 revenue growth
+64.0%
DeclineStrong growth
↑ 4-year growth streakBest: +143.7% (FY2023)Worst: -8.2% (FY2021)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q2 2026$387.5M+51.9%
Q1 2026$305.1M+56.4%
Q4 2025$306.4M+64.3%
Q3 2025$272.3M+70.0%
Q2 2025$255.1M+36.7%
Q1 2025$195.1M+107.5%
Q4 2024$186.5M+134.7%
Q3 2024$160.2M+66.9%
Seasonal Revenue Pattern (fiscal quarters)
Q1
19%
Q2
22%
Q3
24%
Q4
35%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2021)

LEGN's revenue distribution by segment and geography for fiscal year 2021

By Product/Segment

Licensing Of Intellectual Property100.0%

By Geography

UNITED STATES96.6%
CHINA3.4%

LEGN Revenue Analysis (2017–2025)

Current Revenue & Growth

As of October 3, 2026, Legend Biotech Corporation (LEGN) generated trailing twelve-month (TTM) revenue of $1.27 billion, reflecting explosive growth of +51.9% year-over-year. The most recent quarter (Q2 2026) recorded $387.5 million in revenue, up 27.0% sequentially.

Historical Growth Trajectory

LEGN's 5-year compound annual growth rate (CAGR) stands at +68.8%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +106.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Legend Biotech Corporation's highest annual revenue of $1.03 billion was recorded in 2025, an all-time high.

Revenue by Segment

LEGN's revenue is primarily driven by Licensing Of Intellectual Property (100%). With over half of revenue concentrated in Licensing Of Intellectual Property, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including FATE (-23.4% YoY), CRSP (-64.2% YoY), and BEAM (+158.9% YoY) — LEGN has outperformed the peer group in revenue growth. Compare LEGN vs FATE →

LEGN Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
LEGN logoLEGNCurrent$1.3B+51.9%+68.8%-13.3%
FATE logoFATE$7M-23.4%-26.7%-2222.4%
CRSP logoCRSP$4M-64.2%+37.3%-16191.4%
BEAM logoBEAM$140M+158.9%+466.3%-274.6%
NTLA logoNTLA$68M+12.6%+3.1%-651.7%
EDIT logoEDIT$41M+20.8%-14.9%-245.2%
Best in groupLowest in group

LEGN Historical Revenue Data (2017–2025)

1–9 of 9 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$1.03B+64.0%$620.8M60.3%$-136,500,000-13.3%
2024$627.2M+120.0%$392.7M62.6%$-303,243,000-48.3%
2023$285.1M+143.7%$140.9M49.4%$-439,485,000-154.1%
2022$117.0M+70.0%$51.6M44.1%$-455,620,000-389.4%
2021$68.8M-8.2%$68.8M100.0%$-392,287,000-570.0%
2020$75.0M+21.4%$75.0M100.0%$0-
2019$61.8M+25.8%$61.8M100.0%$-132,514,000-214.4%
2018$49.1M+108.2%$49.1M100.0%$-1,534,000-3.1%
2017$23.6M-$23.7M100.4%$13.8M58.4%
Consensus & Technical Research Suite
Open LEGN Terminal

LEGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

9+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LEGN — Frequently Asked Questions

Quick answers to the most common questions about buying LEGN stock.

Is LEGN's revenue growth accelerating or slowing?

LEGN revenue growth is accelerating. TTM revenue reached $1.3B, up +51.9% year-over-year — ahead of the 5-year CAGR of +68.8%. This indicates the business is expanding faster than its historical baseline.

What is LEGN's revenue history from 2017 to 2026?

Legend Biotech Corporation (LEGN) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $1.3B, growing at +51.9% YoY. The 5-year CAGR is +68.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is LEGN's long-term revenue growth rate (CAGR)?

Legend Biotech Corporation's 5-year revenue CAGR of +68.8% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +51.9% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LEGN.

Why does LEGN's quarterly revenue fluctuate?

LEGN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Legend Biotech Corporation's revenue data from 2017 to 2026 shows full historical quarterly detail on this page.

How is LEGN's revenue distributed by segment?

LEGN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does LEGN's revenue compare to industry peers?

Legend Biotech Corporation (LEGN) with TTM revenue of $1.3B and +51.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.